Pharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354 in healthy human subjects: implications for selection of clinical dose.

Dairaghi, D J; Zhang, P; Wang, Y; Seitz, L C; Johnson, D A; Miao, S; Ertl, L S; Zeng, Y; Powers, J P; Pennell, A M; Bekker, P; Schall, T J; Jaen, J C

Dairaghi, D J; Zhang, P; Wang, Y; Seitz, L C; Johnson, D A; Miao, S; Ertl, L S; Zeng, Y; Powers, J P; Pennell, A M; Bekker, P; Schall, T J; Jaen, J C.

Affiliation

Dairaghi DJ; ChemoCentryx, Inc., Mountain View, California, USA. ddairaghi@chemocentryx.com

Clin Pharmacol Ther ; 89(5): 726-34, 2011 May.

Article in En | MEDLINE | ID: mdl-21451509

Subject(s)

Inflammation Mediators/pharmacology; Inflammation Mediators/pharmacokinetics; Quinoxalines/pharmacology; Quinoxalines/pharmacokinetics; Receptors, CCR1/antagonists & inhibitors; Adult; Animals; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Inflammation Mediators/administration & dosage; Male; Middle Aged; Monocytes/drug effects; Monocytes/metabolism; Monocytes/pathology; Protein Binding/physiology; Quinoxalines/administration & dosage; Rabbits; Rats; Rats, Wistar; Receptors, CCR1/metabolism; Young Adult

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quinoxalines / Inflammation Mediators / Receptors, CCR1 Type of study: Clinical_trials Limits: Adult / Animals / Female / Humans / Male / Middle aged Language: En Journal: Clin Pharmacol Ther Year: 2011 Document type: Article

Fulltext

XML

PubMed Links

Search on Google